Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	443.66	332.36	280.38	231.37	265.99	7.14
Cash & Cash Equivalents	443.66	332.36	280.38	231.37	265.99	7.14
Cash Growth	25.77%	18.54%	21.18%	-13.02%	3627.97%	-69.50%
Receivables	0.23	0.14	0	18	0	0.92
Other Current Assets	19.25	14.79	5.39	2.07	1.74	0.87
Total Current Assets	463.13	347.29	285.77	251.44	267.73	8.93
Property, Plant & Equipment	19.43	19.47	17.57	2.4	1.6	1.91
Other Long-Term Assets	3.26	3.26	3.45	1.41	0.12	0.12
Total Long-Term Assets	22.69	22.73	21.01	3.81	1.72	2.03
Total Assets	485.82	370.03	306.78	255.25	269.44	10.96
Accounts Payable	4.99	5.45	3.34	3.65	2.15	2.09
Current Debt	1.05	1.01	0.46	0.86	0.42	0.38
Other Current Liabilities	12.68	17.92	12.75	7.34	4.61	2.02
Total Current Liabilities	18.72	24.37	16.55	11.85	7.18	4.49
Long-Term Debt	13.15	13.44	12.81	0.23	0.48	0.9
Other Long-Term Liabilities	0	0	0	0	0.06	5.08
Total Long-Term Liabilities	13.15	13.44	12.81	0.23	0.54	5.97
Total Liabilities	31.87	37.81	29.36	12.08	7.72	10.46
Total Debt	14.2	14.44	13.27	1.09	0.9	1.28
Debt Growth	1.50%	8.88%	1113.72%	21.58%	-29.49%	61.80%
Retained Earnings	-424.54	-381.43	-228.43	-123.76	-65.01	-19.65
Shareholders' Equity	453.95	332.21	277.42	243.17	261.72	-19.45
Net Cash / Debt	429.45	317.92	267.11	230.28	265.09	5.86
Net Cash / Debt Growth	26.77%	19.02%	16.00%	-13.13%	4423.75%	-74.07%
Net Cash Per Share	12.03	10.80	10.58	9.87	17.10	2.52
Working Capital	444.41	322.92	269.22	239.59	260.54	4.44
Book Value Per Share	12.72	11.28	10.99	10.42	16.88	-8.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).